Nordic Nanovector: Second Quarter Report 2014
Please find enclosed the report for the second quarter 2014.
Highlights for second quarter 2014:
• The lead product candidate Betalutin™ has been granted orphan drug designation for treatment of follicular lymphoma in Europe and in the USA.
Help employers find you! Check out all the jobs and post your resume.